Marie-Francoise Doursout

Marie-Francoise Doursout

Auto-generated profile, based on publicly available information

Marie-Francoise Doursout

Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Immune Network
Verified
Journal Article
Open access
PDF file
ASAnthony Shadid
Anthony Shadid
KHKathryn D. Hok
Kathryn D. Hok
ADAleksey Y. Domozhirov
Aleksey Y. Domozhirov
TMTingting Mills
Tingting Mills
MDMarie-Françoise Doursout
Marie-Françoise Doursout
PSPooja Shivshankar
Pooja Shivshankar
Shadid A, et al. Immune Netw. 2025 Aug;25(4):e32. https://doi.org/10.4110/in.2025.25.e32

1 September 2025 in Movement Disorders
Verified
Journal Article
Open access
MSMya Caryn Schiess
Mya Caryn Schiess
JSJessika Suescun
Jessika Suescun
JMJuan D. Martinez‐Lemus
Juan D. Martinez‐Lemus
CGCharles Green
Charles Green
TTTia S. Thomas
Tia S. Thomas
TETimothy Ellmore
Timothy Ellmore
Background: Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo‐hMSCs) may reduce neuroinflammation and improve motor symptoms. Objectives: To evaluate the efficacy of repeated intravenous doses of 10 × 10 6 /kg allo‐hMSCs in improving motor symptoms in patients with PD (PwP). Methods: In this phase 2, randomized, placebo‐controlled trial (November 2020–July 2023), mild‐to‐moderate PwP received either three allo‐hMSC infusions, one placebo followed by two allo‐hMSC infusions, or three placebo infusions at 18‐week intervals. Follow‐up lasted 88 weeks. The primary outcome was a >70% posterior probability (PP) of a difference in the proportion of participants with ≥5‐point improvement in OFF‐medication Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) at week 62. Bayesian analysis was conducted using R v4.2.0. Results: Forty‐five PwP were enrolled. A larger proportion of subjects achieved a ≥5‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with placebo at week 62 (mean difference [MD]: 5.0%, PP = 93.7%), translating to a 16.9‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with a 14.6‐point improvement in the placebo arm. Conversely, fewer subjects in the two‐infusion arm compared with placebo showed ≥5‐point improvement at week 62 (MD: –62.4%, PP ≥ 99.9%), translating to only a 3.9‐point improvement in MDS‐UPDRS‐III in the two‐infusion arm. However, improvement in MDS‐UPDRS‐III was seen across all treatment arms. Adverse events were mild and transient. Conclusions: Three infusions of 10 × 10 6 allo‐hMSCs/kg improved motor function in mild‐to‐moderate PwP, while two infusions showed less improvement than placebo. To address this discrepancy, future studies should conduct functional potency assays to understand batch‐to‐batch variability affecting clinical efficacy. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 January 2026 in Immune Network
Verified
Journal Article
Open access
PDF file
HRHaydn Emily Rich
Haydn Emily Rich
YLYi-Dong Li
Yi-Dong Li
KHKathryn D. Hok
Kathryn D. Hok
SMStacey L. Mueller-Ortiz
Stacey L. Mueller-Ortiz
ADAleksey Y. Domozhirov
Aleksey Y. Domozhirov
PSPooja Shivshankar
Pooja Shivshankar
Rich HE, et al. Immune Netw. 2026 Apr;26(2):e4. https://doi.org/10.4110/in.2026.26.e4

1 January 2026 in Immune Network
Verified
Journal Article
Open access
PDF file
NCNarsi Chokshi
Narsi Chokshi
KHKathryn D. Hok
Kathryn D. Hok
LGLavanya Gunamalai
Lavanya Gunamalai
NCNathan K. Chen
Nathan K. Chen
ASAnthony Shadid
Anthony Shadid
PSPooja Shivshankar
Pooja Shivshankar
Chokshi N, et al. Immune Netw. 2026 Oct;26(5):e38. https://doi.org/10.4110/in.2026.26.e38